Personalized Medicine and Inhibition ofEGFRSignaling in Lung Cancer
Year: 2009
Type: editorial
Abstract: The concept underlying much of cancer therapy is that patients with specific types and stages of cancer should be treated according to standardized, predetermined protocols. However, recent advances in drug development, pharmacogenomics, and the molecular characterization of tumors — including genomewide RNA expression, DNA copy-number and sequence analyses, and microRNA and proteomic profiling — have the potential to allow individualized selection of treatment as determined by the characteristics of the patient and the tumor.In principle, targeted therapies attack cancer-cell–specific attributes that are essential for growth or survival (“oncogene addiction”) and avoid the potentially severe side effects of conventional cytotoxic . . .
Source: New England Journal of Medicine
DOI: 10.1056/nejme0905763
Author: Adi F. Gazdar
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: National Cancer Institute
OpenAlex ID: W1970015742
